A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response

Bing Feng; Li Tang

doi:10.1002/ctm2.70154

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70154 DOI: 10.1002/ctm2.70154

COMMENTARY

A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response

Bing Feng ¹^,²^,³^,^†
, Li Tang ¹^,²^,^†

Author information +

History +

PDF

Keywords

cancer immunotherapy / curative response / Type 2 immunity

Cite this article

Download citation ▾

Bing Feng, Li Tang. A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response. Clinical and Translational Medicine, 2025, 15(1): e70154 DOI:10.1002/ctm2.70154

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Dupage M, Bluestone JA. Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease. Nat Rev Immunol. 2016;16:149-163.

[2]	Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120-1133.

[3]	Lee EHJ, Murad JP, Christian L, et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat Commun. 2023;14:4737.

[4]	Bai Z, Feng B, McClory SE, et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature. 2024;634:702-711.

[5]	Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19:665-674.

[6]	Mazet JM, Mahale JN, Tong O, et al. IFNγ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. Nat Commun. 2023;14:1-21.

[7]	Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22:158-172.

[8]	Feng B, Bai Z, Zhou X, et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature. 2024;634:712-720.

[9]	Guo Y, Xie YQ, Gao M, et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22:746-756.

[10]	Zhao Y, Chen J, Andreatta M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotech. 2024;42:1693-1704.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.